PredictImmune Awarded £4.3M to Evaluate Ability of Prognostic Test to Guide Crohn’s Treatment

PredictImmune Awarded £4.3M to Evaluate Ability of Prognostic Test to Guide Crohn’s Treatment
PredictImmune has received a £4.3 million (US$5.85 million) grant to fund a prospective clinical trial to determine if its prognostic biomarker test can help personalize treatment strategies for patients with Crohn’s disease, a type of inflammatory bowel disease (IBD). This funding is being provided by the Wellcome Trust, a nonprofit that supports health and medical research. The trial, titled "Predicting Outcomes for Crohn’s disease using a Molecular Biomarker" (PROFILE), is sponsored by Cambridge University Hosp
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *